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A randomised controlled study 
shows supplementation of 
overweight and obese adults with 
lactobacilli and bifidobacteria 
reduces bodyweight and improves 
well-being
D. R. Michael1*, A. A. Jack1, G. Masetti1, t. S. Davies1, K. e. Loxley1, J. Kerry-Smith1, 
J. f. plummer1, J. R. Marchesi2,3, B. H. Mullish  3, J. A. K. McDonald  4, t. R. Hughes5, 
D. Wang6, i. Garaiova1, Z. paduchová7, J. Muchová7, M. A. Good8 & S. f. plummer1
in an exploratory, block-randomised, parallel, double-blind, single-centre, placebo-controlled superiority 
study (ISRCTN12562026, funded by Cultech Ltd), 220 Bulgarian participants (30 to 65 years old) with BMI 
25–34.9 kg/m2 received Lab4P probiotic (50 billion/day) or a matched placebo for 6 months. Participants 
maintained their normal diet and lifestyle. primary outcomes were changes in body weight, BMi, waist 
circumference (WC), waist-to-height ratio (WtHR), blood pressure and plasma lipids. Secondary outcomes 
were changes in plasma C-reactive protein (CRP), the diversity of the faecal microbiota, quality of life 
(QoL) assessments and the incidence of upper respiratory tract infection (URTI). Significant between 
group decreases in body weight (1.3 kg, p < 0.0001), BMI (0.045 kg/m2, p < 0.0001), WC (0.94 cm, 
p < 0.0001) and WtHR (0.006, p < 0.0001) were in favour of the probiotic. Stratification identified greater 
body weight reductions in overweight subjects (1.88%, p < 0.0001) and in females (1.62%, p = 0.0005). 
Greatest weight losses were among probiotic hypercholesterolaemic participants (−2.5%, p < 0.0001) 
alongside a significant between group reduction in small dense LDL-cholesterol (0.2 mmol/L, p = 0.0241). 
Improvements in QoL and the incidence rate ratio of URTI (0.60, p < 0.0001) were recorded for the 
probiotic group. No adverse events were recorded. Six months supplementation with Lab4P probiotic 
resulted in significant weight reduction and improved small dense low-density lipoprotein-cholesterol 
(sdLDL-C) profiles, QoL and URTI incidence outcomes in overweight/obese individuals.
World Health Organisation (WHO) global estimates indicate that 39% of adults are overweight and 13% are obese 
and trends suggest that levels will continue to rise as a result of current dietary habits and sedentary lifestyles1. 
The burden of obesity on primary healthcare providers is substantial and it is estimated that, in England alone in 
2013, excess body weight in women cost £2.2 billion in consultations and £1.9 billion for prescription medica-
tions2. One of the consequences of obesity is the increased incidence of Metabolic Syndrome (MetS) - an umbrella 
term used for a cluster of interrelated metabolic conditions linked with obesity including hypercholesterolaemia, 
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hyperglycaemia and hypertension and associated with diabetes, cardiovascular disease (CVD) and dementia3,4. 
To prevent the development of MetS, adoption of a healthy diet and active lifestyle to avoid excessive weight 
gain is probably the most accessible strategy, but the ongoing rise in global obesity suggests that such lifestyle 
modifications are difficult to adopt by the general population1. The problem is compounded by the difficulty of 
maintaining any weight losses - more than half of the weight lost by an individual is regained within 2 years and 
more than three-quarters is regained within 5 years5.
There is a clear need for other approaches to aid weight loss and/or prevent weight gain/re-gain and one strategy 
is to target the gut microbiome. The trillions of microorganisms residing in the gastrointestinal tract contribute to 
the gut microbiome which plays a critical role in host metabolism through a diverse repertoire of functions includ-
ing the modification and/or liberation of dietary nutrients, immuno-modulation and the regulation of bile acid 
metabolism4. Stability of the gut microbiota is being closely linked with well-being and there is growing evidence 
that microbial imbalance may be linked with the pathogenesis of obesity6 and other metabolic diseases including 
CVD7. Modulation of the composition/functionality/stability of the gut microbiota is being seen as an approach 
to support the prevention of the obesity and MetS development march8. Manipulation of the microbiota can be 
achieved through dietary supplementation with probiotic bacteria (defined by WHO as “live microorganisms 
that, when administered in adequate amounts, confer a health benefit on the host”9). Probiotic supplementation is 
receiving much attention due to a growing body of evidence demonstrating safety and beneficial impacts on many 
aspects of human health including metabolism and immunity10,11. The Lab4P consortium of probiotics (composed 
of Lactobacillus acidophilus, Bifidobacterium bifidum, Bifidobacterium animalis subsp. lactis and Lactobacillus plan-
tarum) has shown cholesterol lowering capability12 and an ability to suppress diet induced weight gain in mice13.
The aim of the current study was to assess the hypothesis that Lab4P daily supplementation over a period 
of 6 months in a healthy overweight/obese free-living human cohort would provide beneficial effects on body 
weight and well-being. Outcomes included changes in anthropometric measurements, plasma lipids and plasma 
C-reactive protein (CRP). Participant perceived quality of life (QoL) and the incidence of upper respiratory tract 
infection (URTI) were monitored as indicators of general well-being with stratification of the study population to 
identify subgroups of participants benefitting most from probiotic supplementation.
Methods
Study approval. This study was conducted according to the principles of the Declaration of Helsinki and 
with approval from the Ethical Committee of Comac Medical, Sofia, Bulgaria (Reference: #127/20.06.2017). The 
study design has been deposited in the ISRCTN registry (ISRCTN12562026 Registration date: 12.03.2019).
Study design. This was a single-centre, double-blind, randomised and placebo-controlled superiority study 
with equal allocation of participants between two parallel study groups. As an exploratory study, there was no 
formal sample size calculation.
Recruitment and randomisation. The study was performed by the trials company Comac Medical. Adults 
aged 30–65 were recruited at the trials facility (Sofia, Bulgaria) between 17/07/17 and 26/07/17. The included 
participants had a waist circumference > 89 cm (women) or > 100 cm (men); a body mass index (BMI, kg/m2) 
between 25 and 34.9; receiving no statins or on stabilised statin therapy for at least 3 months and were willing 
to provide blood samples. Participants were not considered if they were undergoing immunodeficiency/immu-
nosuppressive therapy; had diagnosed diabetes; pregnant or planning pregnancy; had history of ischemic heart 
disease, heart failure, prolonged QTc interval, rhythm, conduction disorders or any other cardiovascular disease 
deemed by the investigator as a risk for the participation in the study; had severe systemic disease (cancer, demen-
tia, advanced organ failure); or had experienced significant unexplained weight loss in the previous 3 months.
All participants entering the study provided written informed consent and received a financial incentive as 
stipulated by the ethics committee. Eligible participants were sequentially assigned an order number and allo-
cated to one of 2 arms of the study in a 1:1 ratio according to a computer-generated random sequence using 
permuted block randomisation with a block-size of four. The randomisation scheme was generated by an inde-
pendent statistician using SAS PROC PLAN (SAS v9.4) and the study product was randomised before arrival at 
the trial site. The allocation sequence was not available to any member of the research team until databases had 
been completed and locked but was held at the trial site in tamper-proof sealed envelopes in case of emergency.
Study product. The active product (Lab4P) comprised Lactobacillus acidophilus CUL60 (NCIMB 
30157), Lactobacillus acidophilus CUL21 (NCIMB 30156), Lactobacillus plantarum CUL66 (NCIMB 30280) 
Bifidobacterium bifidum CUL20 (NCIMB 30153) and Bifidobacterium animalis subsp. lactis CUL34 (NCIMB 
30172) on a base of microcrystalline cellulose at a total of 5 × 1010 colony forming units (cfu) per capsule. The 
placebo product was capsules of microcrystalline cellulose and was identical in appearance to the active prod-
uct. All products were prepared by Cultech Ltd, Port Talbot, UK and packed into induction-sealed high-density 
polyethylene pots and stored at 4–8 °C at the trial site; participants were instructed to refrigerate the supplement 
throughout the study.
intervention. One capsule was taken daily for 6 months (180 days). Participants were asked to consume the 
supplement with food (with or without a cool drink) at any time of the day and to avoid consumption within 
2 hours of any antibiotic intake. Participants were asked to maintain their normal diet and lifestyle throughout 
the study while avoiding the consumption of other probiotic supplements. Participants were provided with pots 
containing 93 capsules at baseline and 3 months and unused capsules were collected at 3 months and 6 months 
for compliance monitoring and enumeration of viable bacteria; no deterioration in the product occurred during 
the intervention period (data not shown).
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outcomes. Primary outcomes were changes from baseline in body weight, waist circumference (WC), blood 
pressure (BP) and plasma lipid profile (total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), 
low-density lipoprotein cholesterol (LDL-C) and triglycerides (TG)) in the total population. Secondary outcomes 
were changes from baseline in plasma CRP level, diversity of the faecal microbiota of volunteers, QoL (as meas-
ured by QoL questionnaire (QoLQ), Supplementary Fig. S1) and the incidence of URTI in the total population. 
Changes in body weight and plasma lipids in a stratified study population were also assessed.
Data and sample collection. The schedule of data and sample collection is shown in Fig. 1a. Physiological 
measurements were taken at each visit. Overnight fasted blood samples were taken at baseline and 6 months. 
Participants were asked to complete daily diaries monitoring URTI symptoms14 throughout the duration of the 
intervention period and QoLQ were completed (Supplementary Fig. S1) at each visit. Participants volunteering 
to provide faecal samples used faecal collection kits for sample collection/transport.
physiological measurements. Body weights were recorded using a calibrated column scale (Seca 709, 
Hamburg, Germany) after the removal of shoes and jackets. Waist circumference was measured 2 fingers below 
the umbilicus and seated blood pressure was measured after 5 minutes respite using a calibrated blood pressure 
monitor (Omron, Kyoto, Japan). Height was measured after the removal of shoes. Efforts were made to ensure the 
time of day when measurements were taken was standardised for each participant.
processing and analysis of blood plasma. Overnight fasted bloods were collected into heparinised tubes 
and plasma separated by centrifugation (2,000 × g, 10 mins) and aliquoted within 1.5 hours of collection (stored 
at 4–8 °C). One aliquot was used to measure TC, HDL-C, LDL-C, TG and CRP immediately (Architect System 
clinical analyser®, Abbot Laboratories, Illinois, USA) and remaining plasma was stored at −80 °C until required. 
Levels of small dense (sd)LDL-C were determined using the sLDL-C-EX “SEIKEN” assay (Randox Laboratories 
Ltd, UK).
processing and analysis of faecal samples. Eighty volunteers provided faecal samples at baseline but 
at 6 months only 64/80 returned samples. Samples were stored refrigerated in anaerobic containers for no more 
than 48 h prior to storage at −80 °C pending analysis. Genomic DNA was extracted using the QIAamp® Fast 
DNA Stool Mini Kit (Qiagen, UK) in accordance with manufacturer’s instructions in conjunction with a cell lysis 
Figure 1. (a) Scheme of sample/data collection and (b) Flow diagram of the study. QoLQ, quality of life 
questionnaire; URTI, upper respiratory tract infection.
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step using Matrix Lysing B tubes (MP Biomedicals, USA) and a FastPrep®−24 bead beater (3 × 30 s cycles (5 m/s) 
with 5 minute intervals). Sample libraries were prepared using the Illumina 16S Metagenomic Sequencing Library 
Preparation Protocol with slight modifications; primers targeting Bifidobacteria species were included during 
amplification of the V1-V2 regions of the 16S rRNA as described elsewhere15 and PCR reactions were cleaned 
and normalised using the SequalPrep Normalization Plate Kit (Life Technologies, Paisley, UK). Sample libraries 
were then quantified using the NEBNext Library Quant Kit for Illumina (New England Biolabs, Hitchin, UK) 
and sequencing was performed on an Illumina MiSeq platform (Illumina Inc., Saffron Walden, UK) using the 
MiSeq Reagent Kit v3 (Illumina Inc) and paired-end 300 base pair (bp) chemistry. Negative and positive control 
reactions were included during sequencing that contained no template DNA or DNA from a reference bacterial 
community respectively.
SeqPrep C++ software was used to join the paired-end R1 and R2 reads. QIIME 1.916 was used to process 
joined reads for quality-filtering with the following parameters: i) maximum of three consecutive base calls with 
Phred <19 (1 error in base calling in 100 bp), ii) a minimum read length including consecutive high-quality base 
calls (Phred > 19) and iii) no “n”-bases allowed. Quality-filtered reads were then aligned against the SILVA17 
closed-reference database 123 release, with 97% cluster identity. To reduce the effect of uneven sampling and 
sequencing, each sample library was rarefied to the smallest library size.
Data management and statistical analysis. Analysis of study outcomes was performed on an 
intention-to-treat basis. Outcome variables with measurements at 3 and 6 months were analysed using a linear 
mixed model (LMM) that included treatment, time, interaction between treatment and time as fixed effects, 
baseline measurement as a covariate, and subject as random effect. The treatment difference at each time point 
with 95% confidence intervals (CI) from t-test was calculated from the LMM. Outcome variables with only meas-
urement at 6 months were analysed using a generalized linear model (GLM) that included treatment as the only 
predictor, and baseline measurement as a covariate, from which the treatment difference at 6 months with 95% 
CI was calculated.
Incidence rates were calculated from daily diaries by dividing the number of episodes of each symptom 
(coughing, runny nose, blocked nose, sore throat, headache, earache, muscle pain, chest wheeze and itchy eyes) 
or antibiotic usage by the number of days in the study and are expressed per 100 person days. Each episode 
comprised a continuous sequence of symptoms or antibiotic usage and was separated from another episode by 
a minimum of 24 h. Incidence rate ratios (IRR) were calculated using a GLM with Poisson distribution and log 
link function.
Covariate adjusted analyses within the LMM/GLM framework as described above were performed on all 
outcomes with age, gender and BMI as covariates. Where appropriate, subgroup analysis was performed by gen-
der, age, BMI and TC level at baseline. Values of p were considered statistically significant when less than 0.05. 
Continuous variables were summarised using mean ± standard deviation (SD). Data analyses were performed 
using SAS® version 9.4 (SAS Institute Inc., Cary, NC, USA).
Statistical analysis of faecal microbiota. Statistical analysis of faecal next generation sequencing 
data was performed by calculating the unique number of operational taxonomic units (OTU) and indices of 
alpha-diversity (Chao1 and Shannon) and beta-diversity (weighted Unifrac) using QIIME 1.9. OTUs with less 
than 15 counts in at least two samples were removed from analysis. Differences in the alpha-diversity indices were 
tested using a mixed-effects linear model, implemented in the lmer function of the lme4 R package, with randomi-
sation (active or placebo), time-point (baseline or 6 months), age, gender and BMI as fixed effects and each partic-
ipant as a random effect. Two-sample comparisons were performed using either the t-test or the non-parametric 
Wilcoxon-Mann-Whitney test according to the normality distribution of the data. Between-group differences 
in beta-diversity were tested with the permutational analysis of variance (PERMANOVA), using the Adonis 
function of the Vegan R package. The assumption of homogeneity of dispersion amongst groups, required by 
PERMANOVA, was tested using the betadisper function in the Vegan R package.
Results
Recruitment. Two hundred and twenty participants were recruited to the study which took place between 
July 2017 and January 2018. There were no drop-outs, exclusions or adverse events in either arm of the study 
(Fig. 1b). Compliance to the intervention was greater than 99% in both arms of the study (as defined by number 
of returned capsules). Over the duration of the study, 12.7% of participants in the active group and 10.9% of par-
ticipants in the placebo group reported antibiotic usage. Baseline demographics of the participants are shown in 
Table 1.
physiological measurements. Changes in body weight, BMI, WC, WtHR and blood pressure from base-
line to 6 months are shown in Fig. 2 (detailed data presented in Supplementary Table S1). Significant between 
group differences at 6 months favouring probiotic supplementation were seen for body weight with a 1.5% weight 
reduction (−1.30 kg, p < 0.0001, Fig. 2a); significant weight loss occurred in the probiotic group (−1.34 kg, 
p < 0.0001) with no significant change in the placebo group. Significant between group reductions in response 
to the probiotic were seen for BMI (−1.5%, p < 0.0001, Fig. 2b), WC (−0.9%, p < 0.0001, Fig. 2c) and WtHR 
(−1.2%, p < 0.0001, Fig. 2d). Decreases in systolic blood pressure (SBP) were observed at 6 months in both groups 
(Active; −1.8%, p = 0.0026, Placebo; −2.2%, p < 0.0001, Fig. 2e) with no significant between group differences.
On the basis of population size, the opportunity for stratification of this population was explored and sub-
group analysis of body weight was conducted: Subgroup 1 (SG1) based on clinically relevant values for overweight 
(BMI < 30 kg/m2, n = 149, SG1a) and obese (BMI ≥ 30 kg/m2, n = 71, SG1b); SG2 male (n = 87, SG2a) and female 
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(n = 133, SG2b); SG3 based on clinical relevant values of normal TC levels (<5.2 mmol/L, n = 108, SG3a), high 
TC levels (5.2–6.19 mmol/L, n = 66, SG3b) and very high TC levels (≥6.2 mmol/L, n = 46, SG3c); SG4 based on 
age: SG4a <40 years, n = 60; SG4b 40–49 years, n = 73 and SG4c ≥ 50 years, n = 87. Significant between group 
differences in body weight in favour of the probiotic were observed for all subgroups after 6 months intervention 
(Fig. 3; detailed data presented in Supplementary Table S2).
For SG1, weight loss from baseline was greater in the overweight participants (BMI <30 kg/m2) supplemented 
with the Lab4P probiotic (−1.9%, −1.5 kg, SG1a) compared to the obese participants (−1.2%, −1.06 kg, SG1b) 
whilst body weight changes for both the placebo overweight and obese groups were <0.1%.
Lab4P supplementation resulted in 1.6% weight loss in women (−1.32 kg, SG2b) and 1.4% in men (−1.36 kg, 
SG2a), with no changes in either placebo group.
In the cholesterol based SGs, significant between group probiotic-mediated weight loss was observed in the 
normal and very high basal cholesterol subgroups. Significant weight loss occurred in the probiotic supplemented 
groups but the responses amongst the placebo groups were inconsistent with trends towards significant weight 
gain in the SG3c placebo group. The very high cholesterol probiotic group lost 1.47 kg (SG3c). Significant weight 
loss occurred in the probiotic receiving participants in sub-groups SG3a and SG3b.
Similarly, within the age stratifications (SG4) significant between group weight loss occurred in all subgroups 
favouring the probiotic with the greatest weight loss in the probiotic supplemented over 50 year olds (−1.72 kg).
plasma biochemistry. Table 2 shows no significant between group changes in plasma biochemistry for 
the total study population at 6 months. TC levels were unchanged in the total study population but LDL-C lev-
els showed a 2.7% increase from baseline in both the active (0.087 mmol/L, p = 0.0667) and the placebo group 
(0.088 mmol/L, p = 0.0618). There were no significant between group differences or changes in levels of HDL-C, 
TG or CRP levels.
The results for the plasma samples collected from the participants in the SG3c subgroup are shown in 
Fig. 4 (detailed data presented in Supplementary Table S3) and indicated significant between group differences 
(−17.6%, −0.220 mmol/L, p = 0.0204) in the levels sdLDL-C as a result of a significant reduction of 15.2%, 
(p = 0.0090) in the active group and marginal increase in the placebo group. There was a between group reduc-
tion in plasma LDL-C levels (−0.305 mmol/L, p = 0.1048) favouring the probiotic that resulted from a significant 
8.7% reduction from baseline in the Lab4P group (−0.396 mmol/L, p = 0.0055) and no significant change in the 
placebo group. TC, HDL and TG did not differ between groups. 
Active (N = 110) Placebo (N = 110)
Mean SD Mean SD
Study Demographics
Age (years) 45.30 10.20 46.52 9.93
Males (n (%)) 44 (40.0%) 43 (39.1%)
Females (n (%)) 66 (60.0%) 67 (60.9%)
Statin usage (n (%)) 1 (0.91%) 2 (1.81%)
Physiological measurements
Body weight (kg) 85.17 13.28 83.97 11.68
Height (m) 1.71 0.09 1.70 0.09
BMI (kg/m2) 29.14 2.73 28.97 2.86
WC (cm) 100.20 9.04 99.52 8.32
WtHR 0.59 0.04 0.59 0.05
SBP (mmHg) 128.64 12.73 130.41 5.76
DBP (mmHg) 79.05 5.29 78.93 5.40
Plasma biochemistry
TC (mmol/L) 5.26 1.11 5.38 1.19
HDL-C (mmol/L) 1.37 0.33 1.33 0.32
LDL-C (mmol/L) 3.22 0.96 3.26 0.99
TG (mmol/L) 1.47 0.99 1.80 1.67
CRP (mg/L) 4.26 7.75 3.14 3.95
QoLQ Score
General Wellness 7.65 1.87 7.75 1.80
State of health 7.97 1.74 8.02 1.74
State of energy 7.65 1.72 7.75 1.83
State of mood 7.82 1.94 7.81 1.77
Sleep quality 7.66 2.15 7.88 1.99
Table 1. Demographic and baseline characteristics of total study population. The data represents the mean ± 
standard deviation (SD) of 110 participants in each group. The number of participants (n) that were male or 
female or taking statin in each group are expressed as a percentage of the total group size.
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faecal microbiota. From the analysis of the 144 faecal samples provided by volunteers, a total of 3,522,472 
reads (mean reads/sample = 24,461 ± 7,399) were obtained after quality filtering resulting in 7,075 unique oper-
ational taxonomic units (OTUs). After rarefaction to the smallest library size 11,001 reads per sample resulted 
in 2,047 OTUs that were grouped into 11 phyla and 205 genera. Fig. 5a,b indicate that there were no significant 
differences in either alpha- or beta-diversity between the probiotic and placebo groups at baseline or 6 months. 
Of the participants providing faecal samples, antibiotic use was reported by 10% participants in the active group 
and 10% participants in the placebo group.
Figure 2. Changes from baseline in (a) body weight, (b) BMI, (c) WC, (d) WtHR, (e) SBP and (f) DBP over the 
duration of the intervention period. Data is presented as mean change from baseline (110 participants per group) 
with 95% CIs and p values were calculated using a LMM. For within group comparisons (vs baseline): **p ≤ 0.01 
and ***p ≤ 0.001. For between group comparisons (active vs placebo): ###p ≤ 0.001. BMI, body mass index; WC, 
waist circumference; WtHR, waist-to-height ratio; SBP, systolic blood pressure; DBP, diastolic blood pressure.
Figure 3. Forest plot of between group changes in body weight in the stratified subgroups at 6 months. Data 
is presented as mean change with 95% CIs and p values calculated using a LMM. n, number of participants 
(active/placebo); TC, total cholesterol; CI, confidence interval.
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Quality of Life. In the total population, supplementation with the probiotic improved General Wellness 
scores by 6.3% (p = 0.0091) and 5.6% (p = 0.0261) at 3 months and 6 months respectively (Table 3) compared to 
placebo. For State of Health, State of Energy, and State of Mood, there were also significant between group bene-
fits at 3 months of 5.8% (0.45, p = 0.013), 5.5% (0.42, p = 0.0316) and 5.1% (0.40, p = 0.0337) respectively but no 
differences were observed at 6 months. Sleep quality did not differ between groups. Within group differences in 
QoL scores are provided in Supplementary Table S4.
Incidence rate ratio of URTI symptoms. For the total population, the probiotic reduced the incidence of 
URTI symptoms by 40% (p < 0.0001, Table 4) and analysis of individual URTI symptoms indicates significant reduc-
tions in sneezing (−46%, p < 0.0001), coughing (−33%, p = 0.0073) and blocked nose (−28%, p = 0.0181) together 
with IRR reductions for headache (−32%, p < 0.0001), earache (−52%, p = 0.0173) and muscle ache (−33%, 
p = 0.0225) compared to placebo. Twenty six participants reported antibiotic usage during the intervention period. 
Distribution of these participants was comparable between the groups with 14 in the active and 12 in the placebo.
Discussion
Supplementation of a free-living population of healthy overweight or obese individuals with the Lab4P probiotic 
resulted in significant reductions in body weight, BMI, waist circumference and waist-to-height ratio compared 
to the placebo group. Significant decreases in systolic blood pressure and significant decreases in LDL-C occurred 
in both groups.
The sample size of our study population afforded the opportunity for subgroup stratification with meaning-
ful numbers. Probiotic-mediated weight loss was observed within subgroups with the overweight (SG1a, 1.9% 
Outcome Group Difference (95% CI) % change p value
TC (mmol/L)
Between 0.016 (−0.15, 0.18) 0.29 0.8480
Active −0.009 (−0.12, 0.11) −0.17 0.8809
Placebo −0.025 (−0.14, 0.09) −0.46 0.6738
HDL-C (mmol/L)
Between −0.014 (−0.70, 0.04) −0.99 0.6350
Active 0.005 (−0.03, 0.04) 0.36 0.8094
Placebo 0.018 (−0.02, 0.06) 1.35 0.3614
LDL-C (mmol/L)
Between −0.002 (−0.13, 0.13) 0.00 0.9806
Active 0.087 (−0.01, 0.18) 2.70 0.0667
Placebo 0.088 (0.00, 0.18) 2.70 0.0618
TG (mmol/L)
Between 0.153 (−0.10, 0.41) 8.69 0.2393
Active 0.020 (−0.16, 0.20) 1.36 0.8326
Placebo −0.132 (−0.31, 0.05) −7.33 0.1480
CRP (mg/L)
Between −0.283 (−1.37, 0.81) −7.35 0.6092
Active −0.199 (−0.97, 0.57) −4.67 0.6100
Placebo 0.084 (−0.68, 0.85) 2.68 0.8302
Table 2. Changes in plasma lipids and CRP from baseline in the total population at 6 months. Data is presented 
as mean change (110 participants per group) with 95% CIs and p values calculated using a GLM. CI, confidence 
interval; TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein 
cholesterol, TG, triglycerides; CRP, C-reactive protein.
Figure 4. Forest plot of between group changes in plasma biochemistry in SG3c (TC ≥ 6.2 mmol/L) at 6 
months. Data is presented as mean change with 95% CIs and p values were calculated using a GLM. n, number 
of participants (active/placebo); TC, total cholesterol; HDL-C, high-density lipoprotein cholesterol; LDL-C, 
low-density lipoprotein cholesterol; sdLDL-C, small dense LDL-C, TG, triglycerides; CI, confidence interval.
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loss), female (SG2b, 1.6% loss), hypercholesterolaemic (SG3c, 2.5% loss) and over 50 s (SG4c, 2.0% loss) groups 
presenting with the greatest weight decreases. No significant weight changes were observed in any of the placebo 
subgroups but a tendency towards significant weight loss was seen in the high basal cholesterol subgroup (SG3b) 
and a tendency towards significant weight gain was observed in the very high basal cholesterol subgroup (SG3c).
Despite significant changes in the anthropometric characteristics, no changes in plasma levels of TC, LDL-C, 
HDL-C, TG nor CRP were observed either between the groups or over the intervention period for the total 
study population. But in the very high cholesterol sub-group SG3c, reductions in plasma LDL-C were observed 
within the probiotic group and reductions in sdLDL-C were observed between groups favouring the probiotic 
supplementation.
Globally it is estimated that 1.9 billion adults are overweight with 650 million of these categorised as obese1. 
Our study is one of the first to report the impact of a multi-strain probiotic on weight loss in response to 6-months 
supplementation in a cohort of healthy, overweight and obese, free-living (no dietary or lifestyle restrictions) 
subjects. More weight loss occurred in the overweight subjects (SG1a) compared with the obese (SG1b) receiv-
ing probiotics agreeing with the meta-analysis findings of Koutnikova and colleagues of greater weight loss in 
probiotic supplemented overweight participants than obese10. No weight loss was observed at the midpoint (3 
months) of our study as has been shown in a number of short-term probiotic studies in free-living overweight/
obese subjects18–20. The association between longer intervention periods and weight loss has been seen in other 
Figure 5. Diversity within the faecal microbiota of the active and placebo groups over the duration of the 
study. (a) Box-and-whisker plot showing the Chao1 and Shannon diversity (alpha-diversity) and (b) a non-
metric dimensional scaling (NMDS) plot showing the weighted unifrac (beta-diversity) of the active group and 
placebo group at baseline and 6 months were generated and differences were assessed with PERMANOVA; 
statistical outliers are represented as black dots and no significant changes were observed. Ellipses represent 
the 95% confidence interval. The data represents 80 samples at baseline (43 active and 37 placebo) and 
64 samples at 6 months (35 active and 29 placebo) from which a total of 3,522,472 reads (mean reads per 
sample = 24,461 ± 7,399) were retained after quality filtering and 7,075 unique OTUs were identified and 
quantified (0.1 non-zero values fraction). 11,001 reads per sample were obtained after rarefaction to the smallest 
library size. Filtering of the low-abundant OTUs retained 2,047 OTUs that were grouped into 11 phyla and 205 
genera.
Outcome
3 months 6 months
Difference (95% CI) % change p value Difference (95% CI) % change p value
General Wellness 0.49 (0.12, 0.85) 6.34 0.0091 0.42 (0.05, 0.78) 5.56 0.0261
State of Health 0.45 (0.10, 0.81) 5.78 0.013 0.24 (−0.12, 0.59) 3.03 0.1939
State of Energy 0.42 (0.04, 0.81) 5.53 0.0316 0.09 (−0.30, 0.47) 1.25 0.6610
State of Mood 0.40 (0.03, 0.76) 5.11 0.0337 0.08 (−0.29, 0.44) 1.01 0.6747
Sleep Quality 0.25 (−0.22, 0.71) 3.20 0.2997 −0.22 (−0.68, 0.25) −2.56 0.3569
Table 3. Changes from baseline in quality of life questionnaire (QoLQ) scores in the total study population. 
Data is presented as mean changes (110 participants per group) with 95% CIs and p values were calculated using 
a LMM. CI, confidence interval.
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meta-analyses21–24. Supplementation with Lab4P had a greater impact on females (SG2b), who lost more weight 
than males (SG2a). Similar observations have been made in diet-restricted probiotic intervention studies and are 
thought to reflect differences in gut microbiota composition and/or energy utilisation between sexes25,26.
In the most recent meta-analyses detailing probiotics and weight loss, body weight reductions up to 1.05 kg 
and BMI reductions up to 0.55 kg/m2 have been reported for overweight/obese subjects10,22,27. Studies focusing 
on free-living overweight and/or obese participants present variable outcomes18–20,28–34 with many performed in 
Asian populations18,29–34. In overweight and/or obese Japanese29–31 or Korean subjects32–34 significant reductions in 
body weight and/or BMI (0.6 to 1.24 kg; 0.23 to 0.45 kg/m2, respectively) have been reported in 12-week probiotic 
studies. No changes were observed in the body weights of overweight/obese Finnish participants supplemented 
with Bifidobacterium animalis ssp. lactis 420, for 24 weeks28 nor in overweight Japanese subjects supplemented 
with Bifidobacterium breve B3 for 12 weeks18. In a 6-week study with Polish participants (BMI ≈25 kg/m2) 
supplemented with Lactobacillus plantarum 299 v, no significant changes in weight/BMI19 were reported nor in a 
4 week study with lean (BMI <25 kg/m2) and obese (BMI ≥35 kg/m2) German participants supplemented with 
Lactobacillus reuteri SD586520. Depommier et al. (2019) supplemented obese individuals with metabolic disease 
with a gut-derived strain of Akkermansia muciniphila, which is an organism believed to be linked to weight man-
agement, and they observed non-significant body weight reductions after 3 months35.
Waist circumference and WtHR ratio are used in clinical practice as markers of visceral adiposity36, closely 
associated with diabetes and CVD37. Supplementation with Lab4P resulted in significant reductions in WC and 
WtHR for the total population and similar outcomes have been reported in a number of probiotic intervention 
studies18,29–31,33 with changes sometimes occurring in the absence of body weight reduction18,28.
The proposed mechanisms of action for probiotic-mediated weight loss includes the modulation of the com-
position of the gut microbiota and the production of short chain fatty acids, the regulation of energy homeo-
stasis and/or satiety, improved gut barrier function and the interruption of bile acid metabolism in the host38. 
We did not detect any gross changes in the faecal microbiota in response to the probiotic. Khalesi et al. (2019) 
observed that probiotic supplementation in healthy adults may not result in changes in the composition of the 
gut microbiota11.
It has been shown that the presence of bacteria with bile salt hydrolase (BSH) activity can mediate the 
deconjugation of bile acids that has been implicated in the prevention of weight gain39. The Lab4P consortium 
has previously been shown to possess bile salt hydrolase activity12,13 and in C57BL/6J mice fed a high fat diet 
Incidence Rate (per 100 person days)
p valueActive Placebo
URTI Symptoms 1.30 2.16
   IRR (95% CI) 0.60 (0.52, 0.70) <0.0001
Individual URTI symptoms
 Sneezing 0.71 1.31
   IRR (95% CI) 0.54 (0.44, 0.66) <0.0001
 Cough 0.38 0.57
   IRR (95% CI) 0.67 (0.50, 0.90) 0.0073
 Runny nose 0.46 0.52
   IRR (95% CI) 0.89 (0.67, 1.18) 0.4268
 Blocked nose 0.46 0.64
   IRR (95% CI) 0.72 (0.55, 0.95) 0.0181
 Sore Throat 0.25 0.31
   IRR (95% CI) 0.80 (0.55, 1.17) 0.2512
Other symptoms
 Headache 1.08 1.58
   IRR (95% CI) 0.68 (0.58, 0.81) <0.0001
 Earache 0.08 0.17
   IRR (95% CI) 0.48 (0.27, 0.88) 0.0173
 Muscle pain 0.28 0.42
   IRR (95% CI) 0.67 (0.48, 0.95) 0.0225
 Chest wheeze 0.09 0.15
   IRR (95% CI) 0.62 (0.34, 1.12) 0.1112
 Itchy eyes 0.19 0.23
   IRR (95% CI) 0.80 (0.52, 1.24) 0.3218
Antibiotic usage 0.08 0.08
   IRR (95% CI) 0.94 (0.46, 1.89) 0.8552
Table 4. Incidence rates of URTI in the total study population. Data is presented as incidence rate or incidence 
rate ratios (IRR) of 110 participants per group with 95% CIs and p values were calculated using a GLM with 
Poisson distribution and log link function. CI, confidence interval.
1 0Scientific RepoRtS |         (2020) 10:4183  | https://doi.org/10.1038/s41598-020-60991-7
www.nature.com/scientificreportswww.nature.com/scientificreports/
with/without Lab4P, increased faecal deconjugated bile acid levels, reduced circulating cholesterol levels and 
reduced diet induced weight gain were observed in the Lab4P fed mice13. Bacterial BSH activity is also linked with 
the reduction of circulating cholesterol levels40.
In our study population, cholesterol and other plasma lipids were not significantly changed and support the 
observation that probiotic supplementation may have little impact in plasma lipids levels in healthy subjects11. 
However, in the hypercholesterolaemic SG3c subgroup (weight loss:1.47 kg), significant plasma LDL-C reduc-
tions of 0.4 mmol/L from baseline were detected in the probiotic group which supports the findings of our pre-
vious mouse studies with Lab4P13. A meta-analysis that assessed the impact of probiotics on lipid levels reported 
comparable changes in circulating LDL-C levels in hypercholesterolaemic subjects41. It has been estimated that 
LDL-C reductions in the region of 1 mmol/L can lead to a 23% reduction in the risk of a CVD-related event42.
One of the underlying causes of CVD is the incidence of atherosclerosis, an inflammatory disease of the vascu-
lature driven by the accumulation of modified forms of LDL-C in artery walls43. LDL is heterogeneous molecule 
comprising a number of discrete particle subclasses that vary in size, density and cholesterol content and the 
small dense LDL-C (sdLDL-C) are considered highly atherogenic44. High circulating levels of sdLDL-C are linked 
to increased CVD risk (irrespective of LDL-C levels45) and an increased susceptibility to obesity and metabolic 
syndrome46. In this study, we recorded between group reductions of sdLDL-C in excess of 17% in hypercholeste-
rolaemic participants (SG3c).
Obesity is also known to impact upon quality of life resulting from factors such as less ability to perform activ-
ities and early fatigue47, increased anxiety, depression and low self-esteem48. Using a modification of an existing 
validated QoL questionnaire49, the results indicated significant improvements in participant scores for general 
wellness, state of health/energy/mood but not sleep quality after 3 months Lab4P supplementation. At 6 months, 
the only difference was in general wellness. QoL improvements have been seen in a study with a probiotic/herbal 
formulation50 and Blissmer et al. (2006) demonstrated improvements in quality of life associated with weight 
loss51.
Excess body weight has been linked to immunological imbalances that can manifest as increased suscep-
tibility to infections including URTIs52; such infections can impart a considerable socioeconomic burden53. 
Probiotics have been found to have a preventative effect on the incidence/severity of URTI54. Our group has 
shown reductions in the incidence of URTI symptoms (sneezing, coughing, blocked nose, runny nose and sore 
throat) in children receiving probiotics14 and these observations have been supported by our in vitro evidence 
of probiotic-mediated immunomodulatory activity55. In the current study, there was significantly less sneezing, 
coughing and blocked nose reported by those participants receiving Lab4P compared to the placebo and the over-
all incidence ratio of URTI was reduced in the probiotic group. Lab4P supplementation also significantly reduced 
the incidence of headache, earache and muscle pain although antibiotic usage did not differ between groups.
Strengths of our study include the large population size allowing subgroup analysis although it should be 
noted that subgroup analysis could have been influenced by the randomisation although similar numbers of 
active and placebo participants were present in each sub group. Another strength is the duration of the interven-
tion period and the unadjusted lifestyle conditions. The limitations of our study include the lack of a formal power 
calculation due to the exploratory nature of the study, its geographical isolation (single centre) and also the free 
living nature of the participants (no dietary control). It is also possible that the inclusion of participants receiving 
antibiotics in our analyses may have influenced our findings although the incidence of antibiotic usage was low 
(≈10% in each arm of the study) and was evenly distributed between both groups. Further work will involve 
assessments of the microbiota of the individuals that received antibiotics.
In summary, this exploratory study has demonstrated that 6 months Lab4P supplementation at 50 billion 
cfu/day significantly reduced bodyweight, BMI, waist circumference and waist-to-height ratio in a free-living 
overweight/obese population with greater weight loss observed in the overweight and the female participants. 
Greatest weight loss together with decreases in small dense LDL-C level were observed in hypercholesterolaemic 
participants. Limited changes in response to supplementation, if any, were observed at 3 months suggesting that 
6 months supplementation at this dosage of Lab4P was needed to effect a meaningful change. Improvements 
in other measures such as participant-perceived QoL and URTI symptoms highlight the holistic benefits of the 
Lab4P supplementation. Further adequately powered target studies are needed to confirm these findings and to 
assess the impact in a multi-centre study.
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